C

Celea Therapeutics

Clinical-stage biopharma developing deupirfenidone for IPF

Director Clinical Program Operations

Program ManagementConfirmed live in the last 24 hours
Full-timeBoston, MA, USA

About the Job

Requirements

  • A bachelor's degree in Life Sciences, Pharmacy, Nursing, Business, Finance, or a related field is required.
  • At least 12 years of progressive experience in biotechnology, pharmaceutical, or clinical research organizations.
  • At least 8 years of experience leading cross-functional clinical development programs.
  • Demonstrated experience managing clinical program budgets exceeding $25 million annually.
  • Experience supporting regulatory submissions and health authority interactions.
  • Deep expertise in clinical development, including global trial design and execution, drug development strategy, and management of multi-regional clinical programs.
  • Strong financial and strategic acumen, including experience in budgeting, forecasting, portfolio management, resource planning, investment evaluation, and balancing scientific, operational, regulatory, and financial priorities.
  • Proven leadership and regulatory expertise, including knowledge of FDA, EMA, and ICH-GCP requirements; ability to lead cross-functional teams, influence stakeholders, drive governance, manage risk, and communicate effectively with executive leadership.

Responsibilities

  • Lead end-to-end planning, execution, governance, and delivery of global clinical development programs, ensuring alignment with strategic objectives, timelines, budgets, and key development milestones.
  • Partner with Clinical Development, Clinical Operations, Medical Writing, Regulatory Affairs, and cross-functional stakeholders to translate development strategies into integrated, executable program plans.
  • Monitor program performance through key performance indicators, dashboards, governance processes, and risk management frameworks, proactively identifying and mitigating operational, financial, regulatory, and execution risks.
  • Develop and manage multi-million-dollar clinical program and portfolio budgets, partnering with Finance on forecasting, long-range planning, resource allocation, scenario analyses, and business case development.
  • Oversee Medical Writing, Trial Master File, contract research organizations, vendors, and strategic partners to ensure high-quality execution, inspection readiness, and achievement of program objectives.
  • Lead vendor management activities, including vendor selection, contract negotiations, performance oversight, relationship management, and optimization of outsourcing strategies.
  • Collaborate with Regulatory Affairs to support global regulatory strategies, health authority interactions, and regulatory submissions while ensuring compliance with Good Clinical Practice, International Council for Harmonisation requirements, FDA, EMA, and other applicable regulations.
  • Drive cross-functional governance, executive communications, resource and capacity planning, and continuous improvement initiatives, providing leadership updates and enabling effective decision-making across the development portfolio.
  • Develop a strategic development plan for the LYT-100 program and support Phase 3 and other registrational clinical studies.

Desired Qualifications

  • An advanced degree is preferred, including an MBA, MPH, PharmD, PhD, MS, or equivalent.
  • Experience in pulmonary asset development.
  • MBA or advanced business training combined with clinical development experience.
  • PMP, PgMP, or similar project or program management certification.
  • Experience in oncology, rare disease, immunology, neuroscience, or other specialized therapeutic areas.
  • Experience supporting product approvals and launch readiness activities.
  • Background in both sponsor organizations and contract research organization environments.
  • Familiarity with portfolio planning software, financial systems, and clinical trial management platforms.

About the Company

Celea Therapeutics

Clinical-stage biopharma developing deupirfenidone for IPF

Celea Therapeutics develops and advances treatments for severe respiratory diseases, focusing on late-stage development of deupirfenidone (LYT-100), a deuterated form of pirfenidone. Its lead program targets idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and is prepared for Phase 3 trials. Deupirfenidone aims to slow lung function decline and improve tolerability by changing how the drug is processed in the body, potentially offering advantages over current IPF therapies. The company pursues a Phase 3 head-to-head trial (SURPASS-IPF) against an approved therapy, supported by Orphan Drug Designations and funding from investors, with PureTech Health retaining a meaningful stake.

Company size
11-50
Company stage
Growth Equity (Non-Venture Capital)
Total funding
$180M
Headquarters
Boston, MA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at Celea Therapeutics

See more jobs